Abbvie's Humira Patent Claims To Be Reviewed By PTAB
The Patent Trial and Appeal Board agreed on Thursday to institute inter partes reviews of five claims within a patent related to AbbVie's autoimmune disease drug Humira, which had sales of...To view the full article, register now.
Already a subscriber? Click here to view full article